<DOC>
	<DOCNO>NCT02765243</DOCNO>
	<brief_summary>Patients refractory and/or recurrent neuroblastoma poor prognosis despite complex multimodel therapy therefore , novel approach urgently need . The investigator attempt treat disease use T cell genetically modify 4th generation lentiviral chimeric antigen receptor ( CAR ) target GD2 ( 4SCAR-GD2 ) . The 4SCAR-GD2-modified T cell recognize kill neuroblastoma recognition GD2 , surface protein express high level neuroblastoma normal tissue . This study evaluate side effect effective dos 4SCAR-GD2 T cell treat refractory and/or recurrent neuroblastoma .</brief_summary>
	<brief_title>Anti-GD2 4th Generation CART Cells Targeting Refractory and/or Recurrent Neuroblastoma</brief_title>
	<detailed_description>Background : Patients refractory and/or recurrent neuroblastoma poor prognosis despite complex multimodal therapy ; therefore , novel curative approach need . The investigator attempt use T cell obtain directly patient , genetically modify express 4th generation GD2-specific chimeric antigen receptor ( 4SCAR-GD2 ) . The chimeric antigen receptor ( CAR ) molecules enable T cell recognize kill neuroblastoma recognition surface antigen , GD2 , express high level neuroblastoma significant level normal tissue . This study evaluate side effect best dose novel 4th generation anti-GD2 CAR T cell refractory and/or recurrent neuroblastoma . Objectives : 1 . Primary : To determine safety feasibility administration 4SCAR-GD2 T cell child neuroblastoma follow cyclophosphamide/fludarabine preparative regimen . 2 . Secondary : 1 . To determine administration 4SCAR-GD2 T cell establish antitumor effect child neuroblastoma receive preparative regimen . 2 . To describe toxicity administration anti-GD2 CAR T cell child without high-burden disease . 3 . To evaluate incidence treatment effect cytokine release syndrome ( CRS ) . 4 . To determine expansion functional persistence 4SCAR-GD2 T cell peripheral blood patient correlation antitumor effect . Eligibility : Patients 1-14 year age , least 10 kg , neuroblastoma recur responded standard therapy deem incurable standard therapy . Design : - Participants screen physical exam medical history . Blood urine sample collect . Imaging study bone marrow aspirate may perform . - Peripheral blood mononuclear cell ( PBMC ) obtain apheresis , T cell activate modified express 4SCAR-GD2 gene . - On Day -7 , PBMC activate enriched T cell , follow 4SCAR-GD2 lentiviral transduction . The total culture time approximately 5-10 day . - Participants receive preparative conditioning regimen comprise cyclophosphamide/fludarabine prepare immune system accept modified CAR T cell . The preparative regimen consist fludarabine 25 mg/m ( 2 ) day -4 , -3 -2 cyclophosphamide 300 mg/m ( 2 ) day-4 , -3 -2 . - Participants receive infusion modify 4SCAR-GD2 T cell closely follow treatment related response . - Participants frequent follow-up visit monitor outcome treatment .</detailed_description>
	<mesh_term>Neuroblastoma</mesh_term>
	<criteria>INCLUSION CRITERIA : 1 . Patients neuroblastoma receive standard firstline therapy judge nonresectable , metastatic , progressive/persistent recurrent . 2 . The GD2 antigen status neuroblastoma determine eligibility . Positive expression define GD2 antibody stain result base immunohistochemistry flow cytometry analysis . 3 . Body weight great equal 10 kg . 4 . Age : ≥1 year ≤ 14 year age time enrollment . 5 . Life expectancy : least 8 week . 6 . Prior Therapy : 1 ) There limit number prior treatment regimen . Any grade 3 4 nonhematologic toxicity previous therapy must resolve grade 2 less . 2 ) Must receive hematopoietic growth factor least 1 week prior mononuclear cell collection . 3 ) At least 7 day must elapse since completion therapy biologic agent , target agent , tyrosine kinase inhibitor metronomic nonmyelosuppressive regimen . 4 ) At least 4 week must elapse since prior therapy include monoclonal antibody . 5 ) At least 1 week since radiation therapy time study entry . 7 . Karnofsky/jansky score 60 % great . 8 . Cardiac function : Left ventricular ejection fraction great equal 40/55 percent . 9 . Pulse Ox great equal 90 % room air . 10 . Liver function : define alanine transaminase ( ALT ) &lt; 3x upper limit normal ( ULN ) , aspartate aminotransferase ( AST ) &lt; 3x ULN ; serum bilirubin alkaline phosphatase &lt; 2x ULN . 11 . Renal function : Patients must serum creatinine less 3 time upper limit normal . 12 . Marrow function : White blood cell count ≥1000/ul , Absolute neutrophil count ≥500/ul , Absolute lymphocyte count ≥500/ul , Platelet count ≥25,000/ul ( achieve transfusion ) . 13 . Patients know bone marrow metastatic disease eligible study long meet hematologic function criterion , marrow disease evaluable hematologic toxicity . 14 . Patients must autologous transduced T cell level great equal 2x10e5 cell per kilogram body weight . 15 . For patient enrol study , parent legal guardian must sign informed consent assent . EXCLUSION CRITERIA : 1 . Existing severe illness ( e.g . significant cardiac , pulmonary , hepatic disease , etc . ) major organ dysfunction , exception grade 3 hematologic toxicity . 2 . Untreated central nervous system ( CNS ) metastasis : Patients previous CNS tumor involvement treat stable least 6 week follow completion therapy eligible . 3 . Previous treatment genetically engineer GD2CAR T cell . 4 . Active HIV , Hepatitis B virus ( HBV ) , Hepatitis C virus ( HCV ) infection uncontrolled infection . 5 . Patients require systemic corticosteroid immunosuppressive therapy . 6 . Patients previously experience severe toxicity cyclophosphamide fludarabine . 7 . Evidence tumor potentially cause airway obstruction . 8 . Inability comply protocol requirement . 9 . Insufficient CAR T cell availability .</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>14 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>neuroblastoma</keyword>
	<keyword>GD2</keyword>
	<keyword>Chimeric antigen receptor</keyword>
	<keyword>Immunotherapy</keyword>
	<keyword>Cyclophosphamide</keyword>
	<keyword>Fludarabine</keyword>
</DOC>